PD-1+CD8+ TILs were rich in tumour-specific cytotoxic T cells, but their distribution and alterations during the progression of HNSCC progression remain unclear.17,18 Understanding the evolutionary stage of a particular tumour may be a necessary step in designing personalised treatment strategies for each patient in the next generation of immunotherapy. Here, CD8A is linked to head and neck squamous cell carcinoma.